"This is a collaborative and institutional-wide effort to improve patient care and accelerate the drug development process," Tsimberidou said. "If the results of IMPACT1 are confirmed, cancer treatment will be transformed and comprehensive molecular profiling will become the standard of care."
The trial is made possible through collaboration with Foundation Medicine, which will provide support with their validated, comprehensive genomic profiling assay, FoundationOne, which detects all classes of genomic alterations in solid tumors across 315 cancer-related genes, as well as 28 other genes often rearranged in cancer. It's expected that more patients will be eligible for targeted therapies given the more comprehensive nature of FoundationOne versus the molecular testing used in IMPACT1.
"Based on the IMPACT1 data, a validated, comprehensive profiling approach has already been adopted by many academic and community-based oncology practices. They use this approach for select groups of cancer patients for whom existing diagnostic and treatment options are inadequate, such as non-small cell lung cancer, cancer of unknown primary and rare tumors," said Vincent Miller, M.D., chief medical officer of Foundation Medicine. "This study has the potential to yield sufficient evidence necessary to support broader adoption across most newly diagnosed metastatic tumors. We're pleased to partner with MD Anderson, who is uniquely positioned to execute this study given their clinical trials expertise."
The effort brings together MD Anderson's capabilities from several departments, including Investigational Cancer Therapeutics, Thoracic/Head and Neck Medical Oncology, Genitourinary Medical Oncology, Melanoma Medical Oncology, Sarcoma Medical Oncology, Gynecologic Oncology, and Endocrine Neoplasia and Hormonal Disorders; and from several divisions, including Diagnostic Imaging, Pathology, Surgical Oncology, and
|Contact: William Fitzgerald|
University of Texas M. D. Anderson Cancer Center